Last reviewed · How we verify

NCT07093996

Endoscopic Pancreatic Duct Stent Placement Versus Conventional Approach in the Treatment of Early Phase Acute Pancreatitis

Not yet recruiting NA Last updated 30 July 2025
What this trial tests

NA trial testing Endoscopic pancreatic duct stent placement in Acute Pancreatitis (AP) in 200 participants. Not yet recruiting.

Timeline
1 September 2025
Primary endpoint
1 December 2026
1 February 2027

Quick facts

Lead sponsorAlmazov National Medical Research Centre
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment200
Start date1 September 2025
Primary completion1 December 2026
Estimated completion1 February 2027
Sites7 locations across China, Russia

Drugs / interventions tested

Conditions studied

Sponsor

Almazov National Medical Research Centre — full company profile →

Who can join

18 and older, any sex, with Acute Pancreatitis (AP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The planned multicenter randomized study is aimed to assess the efficacy and safety of endoscopic pancreatic duct stenting in adult patients with acute pancreatitis. It is planned to include patients with early-stage nonbiliary pancreatitis in the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Pancreatitis (AP)

Currently open trials in the same condition.

Other Almazov National Medical Research Centre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07093996.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing